An interventional study of vNOTES hysterectomy and LSC hysterectomy in Uterine Diseases, sponsored by Imelda Hospital, Bonheiden. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-11.
Sponsored by Imelda Hospital, Bonheiden · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Objective: To randomly compare hysterectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) versus laparoscopy uterus in women with benign gynecological pathology.
Study design: Randomized controlled/single center/single-blinded/parallel-group/non-inferiority/efficacy trial.
Study population: All women aged 18 to 70 years regardless of parity with a non-prolapsed uterus and a benign indication for hysterectomy.
Primary study outcome parameters: successful removal of the uterus by the intended technique.
Secondary outcomes: the proportion of women admitted to the in-hospital ward; postoperative pain scores; the total amount of analgesics used; postoperative infection; per- or postoperative complications; hospital readmission rates; duration of the surgical procedure; incidence and intensity of dyspareunia; sexual wellbeing; health-related quality of life; costs.
l1.Objectives of the HALON Trial The primary research questions of this IDEAL stage 2b efficacy trial are as follows: is a vNOTES (vaginal Natural Orifice Transluminal Endoscopic Surgery) hysterectomy at least as effective compared to the standard transabdominal laparoscopic approach (LSC) for removing a non-prolapsed uterus without the need for conversion to an alternative approach? (non inferiority design)
Secondary research questions are:
2.2. Simple pilot randomized trial. 2.3. Time schedule Based upon the mean number of hysterectomies performed annually for benign gynecological disease at the department of Obstetrics and Gynecology of the participating center (168) the investigators estimate that the duration of recruitment will be 12 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2 years.
2.4. Participating center Department of Obstetrics and Gynecology Imeldahospital Imeldalaan 9 2820 Bonheiden Belgium 3. ELIGIBILITY, CONSENT AND RANDOMIZATION 3.1. Screening and consent prior to surgery All women aged 18 to 70 years, regardless of parity, with a non-prolapsed uterus in need of a hysterectomy for benign indication are eligible for inclusion.
3.2. Determining eligibility All women aged 18 to 70 years, regardless of parity, with a non-prolapsed uterus in need of a hysterectomy for benign indication who provide consent to participation are eligible in the HALON trial and will be randomized before the procedure.
3.3. Randomization If the woman is eligible for the HALON trial, the trial secretary will obtain a randomized allocation the day before surgery. This will be done using a randomization list generated by a free computer software program offered by Research Randomizer (https://www.randomizer.org). The random sequence generation will be concealed using sequentially numbered opaque sealed envelopes. The envelope will be opened by the nurse assistant the day before surgery for practical logistic reasons.
3.4. Patients with strong preference for treatment A minority of women will express a clear preference for one of both treatments (e.g. strong desire to have no scar) and for this reason will not wish to be randomized between surgical treatments. To investigate how outcomes vary by choice, these women could be followed up in exactly the same way as for those women randomized into the HALON trial. A formal non-randomized follow-up of these women will not be done for logistical reasons.
3.5. Stratification of randomization A blocked randomization procedure will be used to avoid chance imbalances for the parameter 'uterine size'.
4.1.1 vNOTES hysterectomy This is the surgical procedure done in the intervention arm of the HALON trial. 4.1.2 LSC hysterectomy This is the surgical procedure done in the control arm of the HALON trial. 5. FOLLOW-UP AND OUTCOME MEASURES 5.1. Clinical assessments 5.1.1 Format PROMs (Patient reported outcomes) will be collected using a postal questionnaire, which will include a combination of disease specific (Pain on sexual intercourse measured by VAS scale and SSFS Scale) and generic measurement instruments (EQ-5D).
The postal questionnaires will be sent from the HALON Trial Office with postage paid envelopes two weeks before the due date. Reminders will be sent to patients if the questionnaire is not returned within one week of the due date and attempts will be made to contact the patient by phone if the questionnaire is not returned by two weeks after the due date.
5.1.2 Timing of assessments The primary outcome will be measured clinically at the end of the surgical procedure. In addition PROMs will take place at baseline (pain on sexual intercourse, health-related quality of life and sexual well being), the evening of the surgical intervention (in-hospital admission), during the first postoperative week (pain by VAS scores and analgetic drugs) and at 3 and 6 months (dyspareunia/ sexual well being/health related quality of life). Clinical physician assessment will take place the evening of the surgical intervention (in-hospital admission) and during the first six weeks following surgery (pelvic infection, surgical complications, hospital readmission rate).
5.2. Primary clinical outcome measure The proportion of women successfully treated by removing the uterus by the intended approach without conversion to another approach, using a dichotomous outcome measure, will be used as a measure of efficacy.
5.3. Secondary clinical outcome measures
The following secondary outcomes will be measured:
Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/abdominal wound closure, as a continuous outcome. 5.4.The direct and indirect costs up to 6 weeks after the hysterectomy of the vNOTES technique compared to LSC.
6.2. Projected accrual and attrition rates Based upon the mean number of hysterectomies performed annually at the department of Obstetrics and Gynecology of the participating center (168) the investigators anticipate that the duration of recruitment will be 12 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2 years. First publication will be possible within four years of trial commencement.
The sample size calculations have allowed for a 15% loss to follow up rate. In order to minimize rates of attrition a dedicated research secretary will be employed to optimize recruitment and follow up.
73 studies on the registry are indexed under Uterine Diseases; 9 are open to participants now.
This study's enrollment of 70 is below the median of 80 across 58 interventional studies indexed under Uterine Diseases.
Browse Uterine Diseases studies →Imelda Hospital, Bonheiden is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vaginal Natural Orifice Transluminal Endoscopic Surgery
Procedure: vNOTES hysterectomy
Laparoscopic hysterectomy
Procedure: LSC hysterectomy
Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
Surgical removal of the uterus by transabdominal laparoscopy
Successful Removal of the Uterus Without Conversion to Another Technique
Successful removal of the uterus without conversion to another technique with or without morcellation
Time frame: Intraoperative
Admission in Hospital for at Least One Night Observation
The number of women admitted in-hospital for at least one night observation based on their own preference after discharge from the day care unit, as a dichotomous outcome. The decision to discharge or to admit to hospital for the night will be based solely on the choice of the woman to return home the same day or stay overnight.
Time frame: Measured on the day of the surgical intervention
Postoperative Pain Scores
Postoperative pain scores, as an ordinal outcome, measured using a Visual Analogue Scale (VAS) twice daily (morning and evening) from day 1 till 7 selfreported by the participating women. VAS scores from 0 to 10 with 0 = no pain and 10= worst pain ever imaginable.
Time frame: The first seven days after the surgical intervention
The Use of Analgetic Drugs for Postoperative Pain
Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.
Time frame: The first week after the surgical intervention
Postoperative Infection
Postoperative infection defined by lower abdominal pain with fever \> 38°C and positive clinical signs or laboratory findings, detected during the first six weeks of surgery, as a dichotomous outcome.
Time frame: The first six weeks after the surgical intervention
Intra- Operative Complications
Intra- operative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome
Time frame: At the time of the surgical intervention
Postoperative Complications
Postoperative complications detected during the first six weeks of surgery, as a dichotomous outcome
Time frame: The first six weeks after the surgical intervention
Hospital Readmission
The number of women readmitted to hospital within six weeks following surgery, as a dichotomous outcome.
Time frame: The first six weeks after the surgical intervention
Duration of the Surgical Intervention
Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/ abdominal wound closure, as a continuous outcome
Time frame: Intraoperative
Vaginal Pain During Sexual Intercourse at Three Months
Incidence of vaginal dyspareunia recorded by the participants at 3 months by self-reporting using a simple questionnaire.
Time frame: At 3 months after the surgical intervention
Vaginal Pain During Sexual Intercourse at Six Months
Incidence of vaginal dyspareunia recorded by the participants at 6 months by self-reporting using a simple questionnaire
Time frame: At 6 months after the surgical intervention
Pelvic Pain During Sexual Intercourse at Three Months
Incidence of pelvic dyspareunia recorded by the participants at 3 months by self-reporting using a simple questionnaire.
Time frame: At 3 months after the surgical intervention
Pelvic Pain During Sexual Intercourse at Six Months
Incidence of pelvic dyspareunia recorded by the participants at 6 months by self-reporting using a simple questionnaire.
Time frame: At 6 months after the surgical intervention
Health-related Quality of Life at Three Months
Health-related quality of life at 3 months by self-reporting the EQ-5D scale.The reported values for the health-related quality of life are self-reported values using the VAS part of the two part EQ-5D-3L questionnaire. The scale ranges from 0 (worst quality) to 100 (best quality).
Time frame: At 3 months after the surgical intervention
Health-related Quality of Life at Six Months
Health-related quality of life at 6 months by self-reporting the EQ-5D scale. The reported values for the health-related quality of life are self-reported values using the VAS part of the two part EQ-5D-3L questionnaire. The scale ranges from 0 (worst quality) to 100 (best quality).
Time frame: At 6 months after the surgical intervention
Sexual Well Being
Sexual wellbeing at baseline, at 3 and 6 months by self-reporting using the SSFS (Short Sexual Function Scale). The SSFS is a questionnaire of 7 open ended questions on sexual wellbeing.
Time frame: At baseline, 3 months and 6 months after the surgical intervention
Direct Costs
Calculating the comparative direct costs in USD of both techniques up to 6 weeks after the surgical intervention
Time frame: Up to 6 weeks postoperative
Between December 9, 2015, and February 23, 2017, 194 women were screened for eligibility
| Milestone | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Started | 35 | 35 |
| Completed | 35 | 35 |
| Not completed | 0 | 0 |
Successful removal of the uterus without conversion to another technique with or without morcellation
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Successful Removal of the Uterus Without Conversion to Another Technique | 35 | 35 |
The number of women admitted in-hospital for at least one night observation based on their own preference after discharge from the day care unit, as a dichotomous outcome. The decision to discharge or to admit to hospital for the night will be based solely on the choice of the woman to return home the same day or stay overnight.
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Admission in Hospital for at Least One Night Observation | 8 | 20 |
Postoperative pain scores, as an ordinal outcome, measured using a Visual Analogue Scale (VAS) twice daily (morning and evening) from day 1 till 7 selfreported by the participating women. VAS scores from 0 to 10 with 0 = no pain and 10= worst pain ever imaginable.
| units on a scale | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| mean pain VAS score day 1 morning | 3.629 (2.877 to 4.380) | 4.200 (3.449 to 4.951) |
| mean pain VAS score day 1 evening | 3.486 (2.815 to 4.157) | 4.456 (3.783 to 5.129) |
| mean pain VAS score day 2 morning | 2.486 (1.876 to 3.096) | 3.543 (2.933 to 4.153) |
| mean pain VAS score day 2 evening | 2.514 (1.947 to 3.082) | 3.343 (2.775 to 3.910) |
| mean pain VAS score day 3 morning | 1.800 (1.261 to 2.339) | 2.800 (2.261 to 3.339) |
| mean pain VAS score day 3 evening | 1.857 (1.335 to 2.379) | 2.914 (2.392 to 3.436) |
| mean pain VAS score day 4 morning | 1.257 (0.746 to 1.769) | 2.286 (1.774 to 2.797) |
| mean pain VAS score day 4 evening | 1.371 (0.867 to 1.876) | 2.457 (1.952 to 2.962) |
| mean pain VAS score day 5 morning | 1.143 (0.643 to 1.642) | 1.914 (1.415 to 2.414) |
| mean pain VAS score day 5 evening | 1.057 (0.562 to 1.553) | 2.086 (1.590 to 2.581) |
| mean pain VAS score day 6 morning | 0.914 (0.421 to 1.407) | 1.914 (1.421 to 2.407) |
| mean pain VAS score day 6 evening | 1.086 (0.591 to 1.580) | 2.000 (1.505 to 2.495) |
| mean pain VAS score day 7 morning | 1.029 (0.525 to 1.532) | 1.567 (1.060 to 2.074) |
| mean pain VAS score day 7 evening | 0.819 (0.290 to 1.348) | 1.693 (1.153 to 2.233) |
Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.
| number of tablets | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| The Use of Analgetic Drugs for Postoperative Pain | 8.0 (0 to 28) | 13.9 (0 to 50) |
Postoperative infection defined by lower abdominal pain with fever \> 38°C and positive clinical signs or laboratory findings, detected during the first six weeks of surgery, as a dichotomous outcome.
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Postoperative Infection | 1 | 2 |
Intra- operative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Intra- Operative Complications | 1 | 0 |
Postoperative complications detected during the first six weeks of surgery, as a dichotomous outcome
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Postoperative Complications | 3 | 13 |
The number of women readmitted to hospital within six weeks following surgery, as a dichotomous outcome.
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Hospital Readmission | 1 | 6 |
Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/ abdominal wound closure, as a continuous outcome
| minutes | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Duration of the Surgical Intervention | 41.1 (21.0 to 130.0) | 75.1 (40.0 to 189.0) |
Incidence of vaginal dyspareunia recorded by the participants at 3 months by self-reporting using a simple questionnaire.
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Vaginal Pain During Sexual Intercourse at Three Months | 8 | 9 |
Incidence of vaginal dyspareunia recorded by the participants at 6 months by self-reporting using a simple questionnaire
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Vaginal Pain During Sexual Intercourse at Six Months | 5 | 8 |
Incidence of pelvic dyspareunia recorded by the participants at 3 months by self-reporting using a simple questionnaire.
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Pelvic Pain During Sexual Intercourse at Three Months | 6 | 8 |
Incidence of pelvic dyspareunia recorded by the participants at 6 months by self-reporting using a simple questionnaire.
| Participants | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Pelvic Pain During Sexual Intercourse at Six Months | 4 | 5 |
Health-related quality of life at 3 months by self-reporting the EQ-5D scale.The reported values for the health-related quality of life are self-reported values using the VAS part of the two part EQ-5D-3L questionnaire. The scale ranges from 0 (worst quality) to 100 (best quality).
| score on a scale | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Health-related Quality of Life at Three Months | 83.8 (40.0 to 100.0) | 79.6 (20.0 to 100.0) |
Health-related quality of life at 6 months by self-reporting the EQ-5D scale. The reported values for the health-related quality of life are self-reported values using the VAS part of the two part EQ-5D-3L questionnaire. The scale ranges from 0 (worst quality) to 100 (best quality).
| score on a scale | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Health-related Quality of Life at Six Months | 87.8 (60.0 to 100.0) | 86.6 (65.0 to 100.0) |
Sexual wellbeing at baseline, at 3 and 6 months by self-reporting using the SSFS (Short Sexual Function Scale). The SSFS is a questionnaire of 7 open ended questions on sexual wellbeing.
Results for this outcome have not been posted.
Calculating the comparative direct costs in USD of both techniques up to 6 weeks after the surgical intervention
| USD | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Direct Costs | 3452.2 (2404.6 to 4897.1) | 3933.6 (2120.6 to 6776.2) |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| vNOTES Hysterectomy | 0/35 (0%) | 0/35 (0%) | 3/35 (8.6%) |
| LSC Hysterectomy | 0/35 (0%) | 2/35 (5.7%) | 11/35 (31.4%) |
| Event | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| vesicovaginal fistulaRenal and urinary disorders | 0/35 | 1/35 |
| Pulmonary embolusRespiratory, thoracic and mediastinal disorders | 0/35 | 1/35 |
| Event | vNOTES Hysterectomy | LSC Hysterectomy |
|---|---|---|
| Urinary tract infectionRenal and urinary disorders | 2/35 | 9/35 |
| Blood transfusionBlood and lymphatic system disorders | 1/35 | 2/35 |
All participants included were women.
| Age, Continuous(Years) | vNOTES Hysterectomy | LSC Hysterectomy | Total |
|---|---|---|---|
| Mean | 46 (24 to 65) | 49 (34 to 68) | 47 (24 to 68) |
| Sex/Gender, Customized(Participants) | vNOTES Hysterectomy | LSC Hysterectomy | Total |
|---|---|---|---|
| Female | 35 | 35 | 70 |
| Race and Ethnicity Not Collected(Participants) | vNOTES Hysterectomy | LSC Hysterectomy | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | vNOTES Hysterectomy | LSC Hysterectomy | Total |
|---|---|---|---|
| Belgium | 35 | 35 | 70 |
| Body Mass Index(kg/m²) | vNOTES Hysterectomy | LSC Hysterectomy | Total |
|---|---|---|---|
| Mean | 26.6 (17.7 to 44.1) | 26.4 (18.6 to 42.9) | 26.5 (17.7 to 44.1) |
| Number of vaginal births(number of vaginal births) | vNOTES Hysterectomy | LSC Hysterectomy | Total |
|---|---|---|---|
| Mean | 1.4 (0 to 4) | 1.3 (0 to 3) | 1.4 (0 to 4) |
| Prior abdominal surgery(Participants) | vNOTES Hysterectomy | LSC Hysterectomy | Total |
|---|---|---|---|
| Count of participants | 20 | 16 | 36 |
| Prior Caesarean section(Participants) | vNOTES Hysterectomy | LSC Hysterectomy | Total |
|---|---|---|---|
| Count of participants | 8 | 5 | 13 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Interim analyses of major endpoints will be supplied, in strict confidence, to an independent Data Monitoring and Ethics Committee (DMEC) along with updates on results of other related studies, and any other analyses that the DMEC may request.
Ran from Dec 2015 to primary completion in Feb 2017, 14 months.
Results were first posted in Jun 2020, 3 years 3 months after primary completion.
Of 28 interventional studies with no phase under Uterine Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 14 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imelda Hospital, Bonheiden